Rethinking Non-Rodent Models – The Göttingen Minipig in Regulatory Toxicology
As toxicologists and non-clinical program teams seek more human-relevant and regulatory-aligned study designs, the Göttingen Minipig is emerging as a strategic non-rodent species for IND-enabling toxicology. With growing use across reproductive, juvenile, and exploratory studies, it offers a compelling alternative grounded in translational value, operational flexibility, and robust background data.
Join Mikkel Lykke Krarup, Chief Scientific Officer of Regulatory Toxicology at Scantox Group, for "Rethinking Non-Rodent Models – The Göttingen Minipig in IND-Enabling Toxicology" presented on June 19, 2025. Registrants will receive access to the on-demand recording.
This webinar explores species selection considerations for nonclinical safety programs and examines where and how the Göttingen Minipig is being adopted in modern regulatory toxicology. From embryofetal development and juvenile studies to safety pharmacology, Mikkel will draw on Scantox Group’s nearly 30 years of experience with the Göttingen Minipig to guide attendees through the scientific rationale, study design considerations, and practical insights supporting its use in IND-enabling toxicology.
Key Learning Objectives
- Examine the scientific and regulatory factors influencing non-rodent species selection.
- Understand how the Göttingen Minipig is used in reproductive, juvenile, and exploratory toxicology.
- Review operational considerations including dose routes, husbandry, litter management, and sample collection.
- Explore real-world study data, background datasets, and video examples of model implementation and animal welfare.
Meet The Presenter
Mikkel is a veterinarian with more than 15 years of experience in the life sciences and over a decade in the contract research industry. As Chief Scientific Officer of Regulatory Toxicology at Scantox Group, he leads scientific strategy and study design for IND-enabling programs, with a primary focus on small molecules and broader application across various therapeutic areas and modalities. His expertise spans regulatory toxicology, translational science, and the operational complexities of outsourced drug development. Mikkel also serves on the Danish Animal Experiments Council, where he contributes to ethical oversight and scientific review of research animal use as an appointed representative of Danish Industry.